Ligand Pharmaceuticals INC 8-K filings

Ligand Pharmaceuticals is set to receive a $2 million milestone payment and royalties on net sales following the FDA approval of Merck's CAPVAXIVE vaccine, which utilizes Ligand's Pfenex technology.

Ligand Pharmaceuticals' stockholders approved an amended stock incentive plan and elected eight directors at their 2024 annual meeting on June 14, 2024.

Ligand Pharmaceuticals finalized the purchase of certain royalty rights from Agenus for $75 million, as per the agreement announced earlier this month.

Ligand Pharmaceuticals announced robust first-quarter financial results for 2024, fueled by its diverse royalty portfolio and strategic investments, while also reaffirming its full-year guidance.

Ligand Pharmaceuticals has entered into an agreement to acquire royalty rights on several partnered oncology programs and a novel immuno-oncology program for $75 million, with an option for an additional $25 million investment.

Ligand Pharmaceuticals has amended and restated its bylaws to align with recent changes in securities regulations and Delaware corporate law.

Ligand Pharmaceuticals reported robust financial results for Q4 and full year 2023, driven by strong royalty revenue and core Captisol sales, and reaffirmed its positive outlook for 2024.